CAR T-cell therapy for refractory ITP and wAIHA
Treatments studied
Part of Blood & lymphatic clinical trials.
This study tests a new CAR T-cell therapy for people with immune thrombocytopenia (ITP) or warm autoimmune hemolytic anemia (wAIHA) that hasn't improved with standard treatments. The goal is to see if this therapy can eliminate the harmful immune cells causing your condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have ITP or wAIHA that has not responded to at least two prior treatments, including steroids and rituximab or thrombopoietic agents.
- Your vital signs and organ functions (heart, lungs, kidneys, liver) must be within acceptable ranges.
- You must not have certain infections (like HIV, hepatitis B/C), serious heart conditions, or other uncontrolled autoimmune diseases.
- You must not have had CAR T-cell therapy or a solid organ transplant before.
- You must agree to use effective birth control during the study and for a period after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment using your own immune cells (CAR T-cells) to stop them from attacking your red blood cells. It is for people with autoimmune hemolytic anemia or Evans syndrome who have not improved after at least 3 previous treatments.
This trial tests a new type of immunotherapy called CAR T-cell therapy that targets two markers on your immune cells (CD19 and BCMA). It is for people with autoimmune hemolytic anemia (AIHA) who have already tried at least 3 standard treatments without success.
This trial tests a new type of cell therapy called UCAR T-cells, which are immune cells engineered to target and destroy the B cells causing your body to attack its own red blood cells. It's designed for patients whose autoimmune hemolytic anemia hasn't responded to at least 3 standard treatments.
This trial tests a new type of immunotherapy called CAR-T cells that target two proteins (CD19 and BCMA) on immune cells. It is for adults with severe ITP that has not improved with other treatments. The goal is to reset the immune system to stop attacking platelets.
This trial tests a new CAR-T cell therapy that targets two proteins (CD19 and BCMA) on immune cells to treat warm antibody autoimmune hemolytic anemia that has not responded to standard treatments. The goal is to see if it is safe and can help control the disease.
This trial tests a new treatment (Inaticabtagene Autoleucel, a type of CAR-T cell therapy) for people with autoimmune hemolytic anemia (AIHA) or Evans syndrome that has not improved after at least three prior treatments. The goal is to see if it can help control the disease.
Hear when a new Cytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.